Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
about
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesPalbociclib - from Bench to Bedside and BeyondProfile of palbociclib in the treatment of metastatic breast cancerTherapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancersTargeting CDK4 and CDK6: From Discovery to TherapyCyclin D as a therapeutic target in cancerFascaplysin as a specific inhibitor for CDK4: insights from molecular modellingIntegrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell LinesAcquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Recent advances of highly selective CDK4/6 inhibitors in breast cancerEmerging therapies for breast cancerThe efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancerCyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progressionPalbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cellsPalbociclib: an evidence-based review of its potential in the treatment of breast cancerClinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.The history and future of targeting cyclin-dependent kinases in cancer therapy.Advances in the targeted therapy of liposarcoma.E2F inhibition synergizes with paclitaxel in lung cancer cell linesTargeting cell cycle regulators in hematologic malignancies.The Role of CDK4/6 Inhibition in Breast Cancer.Targeted therapy in sarcomas other than GIST tumorsMDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer.Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma.The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.Lenvatinib and Palbociclib.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
P2860
Q21245492-24E44AC1-9B98-4EEF-A097-82D9A9D4701CQ26738979-9D4AE427-080F-45EE-8AE1-2379B2620371Q26747737-F2A75573-93B4-499B-AE21-7BCEDED9B560Q27851940-B6857381-EAD4-4C2F-9C98-78ADEE618D36Q27852177-7A79F698-A1C6-457C-BFAC-B36F72831A25Q28069910-CFC2484D-A9A8-44F6-BE08-C41DF3D48DFFQ28082912-10E07308-CA51-4CAB-905A-43FF1BE6235CQ28242623-A2E614E7-375B-4E5A-904A-48218C9860EDQ28482234-FB923092-E26C-4B4E-A1AC-3DE5074A5BA6Q28553930-20CCA7AA-1DE7-472A-9729-3908402670CCQ33571040-7649C503-1D3D-49C5-873F-25A277FAEFA4Q33602076-80A9E012-7423-414F-A046-68464A483D52Q33617949-CE2FA955-0ADF-4438-9A17-D220EA733565Q33638023-EA2B919E-B9EC-4DC7-A2BA-1EB91304A5CEQ33827309-FF8C969F-348F-4008-A2CE-C44D577DC527Q33907588-4A9ED63D-5EAC-4EFE-B62D-3B7C9179ED68Q34004428-97BCCEC8-EDD9-4532-8434-E2BEB2EDE8E3Q34027454-392C5FD4-F4F5-4F91-890A-71A3A707B9AAQ34027724-C8B2840F-A39D-48CA-83E1-4532F10B2328Q34147910-4E796A13-ED27-4E7F-B550-BE044257B599Q34227791-77D7C133-BFB9-4ADD-A1E5-387D90572173Q34394399-1A7A0418-F242-4687-BC82-3E3D70FD89D2Q34460347-5FB5DBB1-15D3-4E69-A1DF-CB50563BFD6EQ34952133-4BFA7B0F-AD46-4422-8644-0BF36456C095Q35169158-8927AE85-124E-4067-ABEE-2BB40255BBFBQ35334436-210D2A5F-CA28-42BA-8BCE-F22D91CB854FQ35586728-FFEA0F98-C989-4FEB-8E59-FAA6B5490285Q35622367-C06EB2DD-C571-40C7-89EB-596548008FADQ35781547-2A796ACE-A354-42D7-AED4-7B9D97C87318Q35835123-622626F7-E34D-4EB8-B84A-456614DC1BB7Q35868272-80EA9014-8951-42A4-864A-65E3B3071AF5Q35899080-4614FB8E-C6DE-4819-AA78-FE58A94D108BQ35931388-22096CD2-7B3C-4873-9FB6-D8BEB0155EC2Q35958082-6897FE78-C808-4895-B658-35AA280F6EC9Q36040449-52E936A0-70DE-43DB-93FC-7AE18DC198B9Q36109982-7338D6C4-8BA7-4626-A01B-99D8DEA1EE0EQ36125976-8DD74FD5-9E68-4E5D-939F-4CB64D880257Q36188947-71466028-DC35-45DE-94E6-857A107A6620Q36189481-B47FEF37-6C29-475D-A5D0-008A9FB99D2BQ36217351-876A009B-6B1D-49A5-87D9-C34852465824
P2860
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@ast
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@en
type
label
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@ast
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@en
prefLabel
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@ast
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@en
P2093
P2860
P356
P1476
Phase I study of PD 0332991, a ...... 3-week cycles (Schedule 2/1).
@en
P2093
G K Schwartz
K D Wilner
M A Dickson
P J O'Dwyer
P M LoRusso
R Courtney
S S Randolph
P2860
P2888
P304
P356
10.1038/BJC.2011.177
P407
P577
2011-05-24T00:00:00Z